NAMUR, Belgium, March 28, 2017 /PRNewswire/ -- Volition America, Inc., a wholly-owned U.S. subsidiary of VolitionRx Limited (NYSE MKT: VNRX), today announced the engagement of Deborah Vollmer Dahlke, DrPH, CEO and President of DVD Associates, LLC, as a strategic consultant. Dr. Vollmer Dahlke's role will be to assist the Company in identifying and securing non-dilutive funding in the State of Texas and elsewhere in the United States. Dr. Vollmer Dahlke has significant experience over the past six years, helping her collaborators and clients receive over $25 million in non-dilutive grants from the Cancer Prevention and Research Institute of Texas (CPRIT).
Dr. Vollmer Dahlke is a Director of the Texas Life Science Foundation, and is actively involved in helping to develop Texas's biotech ecosystem. She has served on the Cancer Alliance of Texas's Executive Committee since 2004, and was Chair from 2012 to 2014. Dr. Vollmer Dahlke was a founding Director of the Research Valley Innovation Center from 2014 to 2015, a biotech and clean energy incubator where she developed the Texas BioLocator app. Dr. Vollmer Dahlke is one of several authors of the current Texas Cancer Plan, one of CPRIT's legislative requirements, aimed at coordinating, prioritizing, and providing an actionable framework to help guide efforts to fight the human and economic burden of cancer in Texas. Dr. Vollmer Dahlke also works with several management consultancies including Deloitte & Touche and McKinsey and Company, Inc.
In addition to her significant public health and technology experience, Dr. Vollmer Dahlke has worked with a number of early stage companies as both a mentor and an entrepreneur. She co-founded Zilliant, a successful enterprise pricing optimization software company, and helped the company raise over $14 million in venture financing.
Jason Terrell, M.D., President and CEO of Volition America, Inc., commented: "We are delighted to be working with Dr. Vollmer Dahlke to help identify and secure funding to further our development of blood-based cancer diagnostic tests for the U.S. The fact that Texas is one of the leading life science states was a key driver in our decision to make this the home of Volition America, Inc. Developing relationships such as this reinforces our decision to be located here and will play a key role in expediting our development plans in the U.S."
Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.
As cancer screening programs become more and more widespread, our products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Media / Investor Contacts
Louise Day, Volition
+44 (0)7557 774620
Scott Powell, Volition
+1 (646) 650 1351
Tirth Patel, Edison Advisors
+1 (646) 653 7035
Rachel Carroll, Edison Advisors
+44 (0)20 3077 5711
Sarah Roberts, Vane Percy & Roberts
+44 (0)1737 821 890
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
SOURCE VolitionRx Limited